Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease.
One and 6 months after vaccination with hepatitis A virus vaccine (HAVRIX 720 Junior), immunologic responses (anti-hepatitis A virus >/=20 mIU/ml) in children with chronic hepatitis C infection seroprotection were 92% (23/25) and 75% (9/12) in children with chronic hepatitis B infection 87% (21/24) and 88% (15/17) and in healthy children 91% (20/22) at both times. A booster dose induced seroprotection in all children.
Majda-Stanislawska
Ewa
E
Department and Clinic of Infectious Diseases and Hepatology, Medical University of Lodz, Lodz, Poland.
Bednarek
Malgorzata
M
Kuydowicz
Jan
J
D000293:Adolescent; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D015331:Cohort Studies; D005260:Female; D006506:Hepatitis A / Q000150:complications / Q000276:immunology* / Q000517:prevention & control; D035922:Hepatitis A Antibodies / Q000276:immunology*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000276:immunology / Q000517:prevention & control; D018937:Hepatitis C Antibodies / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000276:immunology*; D008297:Male; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D018937:Hepatitis C Antibodies; D015164:Vaccines, Inactivated